Role of Human CD4 D1D2 Domain in HIV-1 Infection

REFERENCES

• Allaway, G. P., Davis-Bruno, K. L., Beaudry, G. A., Garcia, E. B., Wong, E. L., Ryder, A. M., Hasel, K. W., Gauduin, M. C., Koup, R. A., McDougal, J. S. (1995). Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 11:533–539.
   PubMed Web of Science ®Google Scholar
• Benjamin, R. J., Waldmann, H. (1986). Induction of tolerance by monoclonal antibody therapy. Nature 320:449–451.
   PubMed Web of Science ®Google Scholar
• Bruno, C. J., Jacobson, J. M. (2010). Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J. Antimicrob. Chemother. 65(9): 1839–1841.
   PubMed Web of Science ®Google Scholar
• Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W., Sawyer, L. S., Hendry, R. M., Dunlop, N., Nara, P. L. (1994). Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024–1027.
   PubMed Web of Science ®Google Scholar
• Calarese, D. A., Scanlan, C. N., Zwick, M. B., Deechongkit, S., Mimura, Y., Kunert, R., Zhu, P., Wormald, M. R., Stanfield, R. L., Roux, K. H., Kelly, J. W., Rudd, P. M., Dwek, R. A., Katinger, H., Burton, D. R., Wilson, I. A. (2003). Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065–2071.
   PubMed Web of Science ®Google Scholar
• Cardoso, R. M., Zwick, M. B., Stanfield, R. L., Kunert, R., Binley, J. M., Katinger, H., Burton, D. R., Wilson, I. A. (2005). Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163–173.
   PubMed Web of Science ®Google Scholar
• Carrel, S., Moretta, A., Pantaleo, G., Tambussi, G., Isler, P., Perussia, B., Cerottini, J. C. (1988). Stimulation and proliferation of CD4+ peripheral blood T lymphocytes induced by an anti-CD4 monoclonal antibody. Eur. J. Immunol. 18:333–339.
   PubMedGoogle Scholar
• Chen, W., Feng, Y., Gong, R., Zhu, Z., Wang, Y., Zhao, Q., Dimitrov, D. S. (2011). Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J. Virol. 85(18):9395–9405.
   PubMedGoogle Scholar
• Daar, E. S., Li, X. L., Moudgil, T., Ho, D. D. (1990). High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA 87:6574–6578.
   PubMed Web of Science ®Google Scholar
• Dalgleish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H., Greaves, M. F., Weiss, R. A. (1984). The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763–767.
   PubMed Web of Science ®Google Scholar
• Dimitrov, A. (2007). Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection. Curr. Opin. Investig. Drugs 8:653–661.
   PubMedGoogle Scholar
• Fouts, T., Godfrey, K., Bobb, K., Montefiori, D., Hanson, C. V., Kalyanaraman, V. S., DeVico, A., Pal, R. (2002). Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. USA 99:11842−11847.
   Google Scholar
• Gardiner, D. F., Huang, Y., Basu, S., Leung, L., Song, Y., Chen, Z., Ho, D. D. (2006). Multiple-site DNA vaccination enhances immune responses in mice. Vaccine 24:287–292.
   PubMedGoogle Scholar
• Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., Montana, J. B., McHale, M., Sullivan, J., Ridgway, C., Felstead, S., Dunne, M. W., van der Ryst, E., Mayer, H.; MOTIVATE Study Teams. (2008). Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429–1441.
   PubMed Web of Science ®Google Scholar
• Gutstein, N. L., Seaman, W. E., Scott, J. H., Wofsy, D. (1986). Induction of immune tolerance by administration of monoclonal antibody to L3T4. J. Immunol. 137:1127–1132.
   PubMedGoogle Scholar
• Hasler, P. (2006). Biological therapies directed against cells in autoimmune disease. Springer Semin. Immunopathol. 27:443–456.
   PubMed Web of Science ®Google Scholar
• Jabado, N., Pallier, A., Le Deist, F., Bernard, F., Fischer, A., Hivroz, C. (1997). CD4 ligands inhibit the formation of multifunctional transduction complexes involved in T cell activation. J. Immunol. 158:94–103.
   PubMedGoogle Scholar
• Jacobson, J. M., Israel, R. J., Lowy, I., Ostrow, N. A., Vassilatos, L. S., Barish, M., Tran, D. N., Sullivan, B. M., Ketas, T. J., O’Neill, T. J., Nagashima, K. A., Huang, W., Petropoulos, C. J., Moore, J. P., Maddon, P. J., Olson, W. C. (2004). Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. 48:423–429.
   PubMed Web of Science ®Google Scholar
• Jacobson, J. M., Kuritzkes, D. R., Godofsky, E., DeJesus, E., Larson, J. A., Weinheimer, S. P., Lewis, S. T. (2009). Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 53:450–457.
   PubMed Web of Science ®Google Scholar
• Khrustalev, V. V. (2010). Levels of HIV1 gp120 3D B-cell epitopes mutability and variability: searching for possible vaccine epitopes. Immunol. Invest. 39:551–569.
   PubMed Web of Science ®Google Scholar
• Kuritzkes, D. R. (2009). HIV-1 entry inhibitors: an overview. Curr. Opin. HIV AIDS 4: 82–87.
   PubMedGoogle Scholar
• Kuritzkes, D. R., Jacobson, J., Powderly, W. G., Godofsky, E., DeJesus, E., Haas, F., Reimann, K. A., Larson, J. L., Yarbough, P. O., Curt, V., Shanahan, W. R. (2004). Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189:286–291.
   PubMed Web of Science ®Google Scholar
• Kwong, P. D., Doyle, M. L., Casper, D. J., Cicala, C., Leavitt, S. A., Majeed, S., Steenbeke, T. D., Venturi, M., Chaiken, I., Fung, M., Katinger, H., Parren, P. W., Robinson, J., Van Ryk, D., Wang, L., Burton, D. R., Freire, E., Wyatt, R., Sodroski, J., Hendrickson, W. A., Arthos, J. (2002). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678–682.
   PubMed Web of Science ®Google Scholar
• Kwong, P. D., Ryu, S. E., Hendrickson, W. A., Axel, R., Sweet, R. M., Folena-Wasserman, G., Hensley, P., Sweet, R. W. (1990). Molecular characteristics of recombinant human CD4 as deduced from polymorphic crystals. Proc. Natl. Acad. Sci. USA 87:6423–6427.
   PubMed Web of Science ®Google Scholar
• Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., Hendrickson, W. A. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648–659.
   PubMed Web of Science ®Google Scholar
• Landovitz, R. J., Angel, J. B., Hoffmann, C., Horst, H., Opravil, M., Long, J., Greaves, W., Fätkenheuer, G. (2008). Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J. Infect. Dis. 198:1113–1122.
   PubMed Web of Science ®Google Scholar
• Maddon, P. J., Dalgleish, A. G., McDougal, J. S., Clapham, P. R., Weiss, R. A., Axel, R. (1986). The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333–348.
   PubMed Web of Science ®Google Scholar
• Moreland, L. W., Pratt, P. W., Bucy, R. P., Jackson, B. S., Feldman, J. W., Koopman, W. J. (1994). Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Arthritis Rheum. 37:834–838.
   PubMedGoogle Scholar
• Ofek, G., Tang, M., Sambor, A., Katinger, H., Mascola, J. R., Wyatt, R., Kwong, P. D. (2004). Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78:10724–10737.
   PubMed Web of Science ®Google Scholar
• Phogat, S., Wyatt, R. T., Karlsson Hedestam, G. B. (2007). Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J. Intern. Med. 262:26–43.
   PubMed Web of Science ®Google Scholar
• Qin, S. X., Cobbold, S., Benjamin, R., Waldmann, H. (1989). Induction of classical transplantation tolerance in the adult. J. Exp. Med. 169:779–794.
   PubMedGoogle Scholar
• Ryu, S. E., Kwong, P. D., Truneh, A., Porter, T. G., Arthos, J., Rosenberg, M., Dai, X. P., Xuong, N. H., Axel, R., Sweet, R. W. (1990). Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature 348:419–426.
   PubMed Web of Science ®Google Scholar
• Saha, P., Barua, B., Bhattacharyya, S., Balamurali, M. M., Schief, W. R., Baker, D., Varadarajan, R. (2011). Design and characterization of stabilized derivatives of human CD4D12 and CD4D1. Biochemistry 50(37):7891–7900.
   PubMedGoogle Scholar
• Sakihama, T., Smolyar, A., Reinherz, E. L. (1995). Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. Proc. Natl. Acad. Sci. USA 92:6444–6448.
   PubMedGoogle Scholar
• Song, R. J., Franco, D., Kao, C. Y., Yu, F., Huang, Y. X., Ho, D. D. (2010). Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J. Virol. 84(14):6935–6942.
   PubMed Web of Science ®Google Scholar
• Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., Srinivasan, K., Sodroski, J., Moore, J. P., Katinger, H. (1996). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100–1108.
   PubMed Web of Science ®Google Scholar
• Tsygankov, A. Y., Broker, B. M., Guse, A. H., Meinke, U., Roth, E., Rossmann, C., Emmrich, F. (1993). Preincubation with anti-CD4 influences activation of human T cells by subsequent co-cross-linking of CD4 with CD3. J. Leukoc. Biol. 54:430–438.
   PubMedGoogle Scholar
• Turner, S., Tizard, R., DeMarinis, J., Pepinsky, R. B., Zullo, J., Schooley, R., Fisher, R. (1992). Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 89:1335–1339.
   PubMed Web of Science ®Google Scholar
• Varadarajan, R., Sharma, D., Chakraborty, K., Patel, M., Citron, M., Sinha, P., Yadav, R., Rashid, U., Kennedy, S., Eckert, D., Geleziunas, R., Bramhill, D., Schleif, W., Liang, X., Shiver, J. (2005). Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J. Virol. 79:1713−l1723.
   PubMedGoogle Scholar
• Walker, L. M., Phogat, S. K., Chan-Hui, P.Y., Wagner, D., Phung, P., Goss, J. L., Wrin, T., Simek, M. D., Fling, S., Mitcham, J. L., Lehrman, J. K., Priddy, F. H., Olsen, O. A., Frey, S. M., Hammond, P. W.; Protocol, G., Principal Investigators, Kaminsky, S., Zamb, T., Moyle, M., Koff, W. C., Poignard, P., Burton, D. R. (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285–289.
   PubMed Web of Science ®Google Scholar
• Wang, J. H., Meijers, R., Xiong, Y., Liu, J. H., Sakihama, T., Zhang, R., Joachimiak, A., Reinherz EL. 2001. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc. Natl. Acad. Sci. USA 98:10799–10804.
   PubMedGoogle Scholar
• Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., Komarova, N. L., Nowak, M. A., Hahn, B. H., Kwong, P. D., Shaw, G. M. (2003). Antibody neutralization and escape by HIV-1. Nature 422:307–312.
   PubMed Web of Science ®Google Scholar
• Zhou, T., Xu, L., Dey, B., Hessell, A. J., Van Ryk, D., Xiang, S. H., Yang, X., Zhang, M. Y., Zwick, M. B., Arthos, J., Burton, D. R., Dimitrov, D. S., Sodroski, J., Wyatt, R., Nabel, G. J., Kwong, P. D. (2007). Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732–737.
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner, S. (2004). Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4: 199–210.
   PubMed Web of Science ®Google Scholar